Rebecca Henderson Net Worth

The estimated Net Worth of Rebecca M Henderson is at least $12.8 Million dollars as of 23 February 2021. Rebecca Henderson owns over 3,046 units of Idexx Laboratories stock worth over $8,698,193 and over the last 21 years he sold IDXX stock worth over $3,803,556. In addition, he makes $298,482 as Independent Director at Idexx Laboratories.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Rebecca Henderson IDXX stock SEC Form 4 insiders trading

Rebecca has made over 18 trades of the Idexx Laboratories stock since 2011, according to the Form 4 filled with the SEC. Most recently he exercised 3,046 units of IDXX stock worth $488,213 on 23 February 2021.

The largest trade he's ever made was exercising 20,000 units of Idexx Laboratories stock on 13 February 2014 worth over $1,248,200. On average, Rebecca trades about 1,607 units every 42 days since 2003. As of 23 February 2021 he still owns at least 17,742 units of Idexx Laboratories stock.

You can see the complete history of Rebecca Henderson stock trades at the bottom of the page.

Rebecca Henderson biography

Dr. Rebecca M. Henderson Ph.D. serves as Independent Director of the Company. Dr. Henderson has been the John and Natty McArthur University Professor at Harvard University since 2011. Before joining Harvard’s faculty, from 1998 to 2009 Dr. Henderson served as the Eastman Kodak Professor of Management, Sloan School of the Massachusetts Institute of Technology. Dr. Henderson is also a research fellow at the National Bureau of Economic Research and a fellow of both the British Academy and of the American Academy of Arts and Sciences. Dr. Henderson holds an undergraduate degree from the Massachusetts Institute of Technology and a PhD in business economics from Harvard University. As a Harvard Business School professor of general management and strategy and an author of both books and articles regarding sustainability, strategy and innovation, Dr. Henderson brings substantial expertise in corporate strategy, sustainability, compensation practices, corporate responsibility and governance issues, with a particular focus on high-technology businesses. This expertise, combined with her deep knowledge of and insight into our businesses, operations and organization from her more than fifteen years of service on the Board, uniquely positions Dr. Henderson to offer valuable insights into the organizational and strategic issues faced by IDEXX.

What is the salary of Rebecca Henderson?

As the Independent Director of Idexx Laboratories, the total compensation of Rebecca Henderson at Idexx Laboratories is $298,482. There are 17 executives at Idexx Laboratories getting paid more, with Jonathan Ayers having the highest compensation of $8,309,800.

How old is Rebecca Henderson?

Rebecca Henderson is 59, he's been the Independent Director of Idexx Laboratories since 2003. There are 7 older and 16 younger executives at Idexx Laboratories. The oldest executive at Idexx Laboratories, Inc. is M. Anne Szostak, 69, who is the Independent Director.

What's Rebecca Henderson's mailing address?

Rebecca's mailing address filed with the SEC is ONE IDEXX DRIVE, , WESTBROOK, ME, 04092.

Insiders trading at Idexx Laboratories

Over the last 22 years, insiders at Idexx Laboratories have traded over $238,711,289 worth of Idexx Laboratories stock and bought 24,695 units worth $3,109,424 . The most active insiders traders include Stuart Essig, Johnny D Powers, and Jonathan W Ayers. On average, Idexx Laboratories executives and independent directors trade stock every 9 days with the average trade being worth of $4,641,291. The most recent stock trade was executed by M Anne Szostak on 5 September 2024, trading 500 units of IDXX stock currently worth $234,685.

What does Idexx Laboratories do?

idexx laboratories, inc. (nasdaq: idxx) is a leader in pet healthcare innovation, serving practicing veterinarians around the world with a broad range of diagnostic and information technology-based products and services. headquartered in southern maine, idexx conducts operations through more than 70 locations around the world, serves customers in over 175 countries, and employs more than 6,000 people. idexx's primary business focuses on pet health, a growing market around the world. idexx products —in-clinic diagnostic tests and instrumentation, reference laboratory and telemedicine consultation services, and practice management software—enhance the ability of veterinarians to provide advanced medical care, improve staff efficiency and to build more economically successful practices. idexx also develops and manufactures diagnostic tests and information for the global production animal industry, including poultry and livestock, as well as tests for the quality and safety of water an

Complete history of Rebecca Henderson stock trades at AMGEN and Idexx Laboratories

Idexx Laboratories executives and stock owners

Idexx Laboratories executives and other stock owners filed with the SEC include:

• Jonathan Ayers,
  Director
• Jonathan Mazelsky,
  President, Chief Executive Officer, Director
• Brian McKeon,
  Chief Financial Officer, Executive Vice President, Treasurer
• Kathy Turner,
  Corporate Vice President and Chief Marketing Officer
• Jonathan J. Mazelsky,
  Pres, CEO & Director
• Sharon Underberg,
  Corporate Vice President, General Counsel, and Corporate Secretary
• Michael Lane,
  Executive Vice President, General Manager, Reference Laboratories and Information Technology
• Brian P. McKeon,
  CFO, Exec. VP & Treasurer
• Giovani Twigge,
  Chief Human Resource Officer, Corporate Vice President
• Dr. Nimrata Khatra Hunt P.E., Ph.D.,
  Exec. VP and GM - Point of Care Diagnostics & Worldwide Operations
• Michael J. Lane,
  Exec. VP and GM of Reference Laboratories & Information Technology
• James F. Polewaczyk,
  Exec. VP & Chief Commercial Officer
• Sharon E. Underberg,
  Exec. VP, Gen. Counsel, & Corp. Sec.
• Lawrence Kingsley,
  Independent Chairman of the Board
• M. Anne Szostak,
  Independent Director
• Daniel Junius,
  Independent Director
• Bruce Claflin,
  Independent Director
• Rebecca Henderson,
  Independent Director
• Sophie Vandebroek,
  Independent Director
• Stuart Essig,
  Independent Director
• Sam Samad,
  Independent Director
• Jonathan W. Ayers,
  Sr. Advisor & Director
• Asha Collins,
  Independent Director
• James Polewaczyk,
  Executive Vice President and Chief Commercial Officer
• Tina Hunt,
  Executive Vice President, General Manager, Point of Care Diagnostics and Worldwide Operations
• Dr. Martin Smith Ph.D.,
  Exec. VP & CTO
• Ken Grady,
  Sr. VP & Chief Information Officer
• Martin Smith,
  Exec. VP & CTO
• Jeffery D. Chadbourne,
  Sr. Director of Accounting & Financial Reporting
• John Hart,
  Sr. VP of Worldwide Operations
• Barry C Johnson,
  Director
• Thomas Craig,
  Director
• William End,
  Director
• Jacqueline Studer,
  CVP, Gen. Counsel & Secretary
• Thomas J Dupree,
  Corporate Vice President
• Michael J Williams,
  Corporate Vice President
• Daniel V Meyaard,
  Corporate Vice President
• Conan R Deady,
  Vice President and Secretary
• Joseph V Vumbacco,
  Director
• William E Iii Brown,
  Corporate Vice President
• William B. Goodspeed,
  Corporate Vice President
• Robert J Murray,
  Director
• Jeffrey Fiarman,
  EVP, GEN COUNSEL & SECRETARY
• Ali Naqui,
  Vice President
• Johnny D Powers,
  Corporate Vice President
• Errol B Desouza,
  Director
• William C Wallen,
  SVP & Chief Scientific Officer
• Quentin J Tonelli,
  Vice President
• S Sam Fratoni,
  Vice President
• Irene C Kerr,
  Corporate Vice President
• Robert S Hulsy,
  Vice President
• Laurel E Labauve,
  Vice President
• Merilee Raines,
  Vice President,CFO & Treasurer
• James L Jr Moody,
  Director
• Jennifer A Joiner,
  Corp VP CAG N American CommOps
• Louis W Pollock,
  Senior Vice President
• Erwin R Jr Workman,
  Executive Vice President
• Nimrata Hunt,
  Executive Vice President
• Irene Chang Britt,
  Director
• Martin Alexander Smith,
  Executive Vice President
• Michael Perkins Johnson,
  EVP and CHRO
• George Fennell,
  SVP, Chief Revenue Officer
• Michael G Erickson,
  Executive Vice President
• Michael Schreck,
  Executive Vice President